Literature DB >> 8359197

Recombinant interleukin-5 induces in vivo airway hyperresponsiveness to histamine in guinea pigs.

A J Van Oosterhout1, I Van Ark, G Hofman, H F Savelkoul, F P Nijkamp.   

Abstract

Interleukin-5-producing CV-1 cells were encapsulated in alginate and injected i.p. in guinea pigs (4 x 10(6)/animal). These cells produced approximately 8 ng interleukin-5 per 4 x 10(6) cells per day. Airway hyperresponsiveness to histamine in vivo was observed 3 and 7 days after administration. The increase in lung resistance after intravenous administration of histamine to guinea pigs was significantly potentiated, by approximately 70 to 90% in interleukin-5-treated animals. In animals treated with antibody to interleukin-5, the administration of interleukin-5-producing CV-1 cells did not induce hyperresponsiveness. The percentage of eosinophils in broncho-alveolar lavage fluid was increased by 100% at 7 days but not at 3 days after administration of interleukin-5-producing CV-1 cells. Antibody to interleukin-5 prevented the broncho-alveolar lavage eosinophilia at 7 days after interleukin-5 administration. It can be concluded that interleukin-5 induces broncho-alveolar lavage eosinophilia and airway hyperresponsiveness and that these phenomena do not occur simultaneously. These data suggest a role for interleukin-5 in the development of airway hyperresponsiveness in bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359197     DOI: 10.1016/0014-2999(93)90475-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Interleukin-5 reduces the expression of uteroglobin-related protein (UGRP) 1 gene in allergic airway inflammation.

Authors:  Yoshihiko Chiba; Achara Srisodsai; Porntip Supavilai; Shioko Kimura
Journal:  Immunol Lett       Date:  2005-02-15       Impact factor: 3.685

2.  Interleukin-5 potentiates sulfidopeptide leukotriene production by human eosinophils.

Authors:  A J Van Oosterhout; A Van Der Poel; L Koenderman; D Roos; F P Nijkamp
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.